Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet

BACKGROUND: In older patients with overactive bladder (OAB), mirabegron, a β(3)-adrenoreceptor agonist, represents an alternative treatment that may have a favorable risk–benefit profile. OBJECTIVES: Our objective was to further examine the safety and tolerability of mirabegron versus placebo treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Herschorn, Sender, Staskin, David, Schermer, Carol R., Kristy, Rita M., Wagg, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473960/
https://www.ncbi.nlm.nih.gov/pubmed/32725584
http://dx.doi.org/10.1007/s40266-020-00783-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473960/
https://www.ncbi.nlm.nih.gov/pubmed/32725584
http://dx.doi.org/10.1007/s40266-020-00783-w

Ejemplares similares